The Food and Drug Administration is reviewing Orchard Therapeutics’ approval application for a gene therapy to treat the rare disease metachromatic leukodystrophy, setting a decision deadline of March 18, 2024, the company said Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,